Abstract
The clinical outlook for adults with acute lymphoblastic leukemia (ALL) has improved with the use of intensive chemotherapy. Complete remissions (CR) are achieved in 80% of adults but the majority relapse on maintenance chemotherapy and a few exhibit primary resistance to induction therapy. This report compares the various salvage treatments and provides guidance in selecting a regimen with the optimum clinical outcome. Regimens using high- dose ara-C (HDAC) in combination with mitoxantrone, amsacrine, or idarubicin are superior to HDAC alone or with L-asparaginase. The sequential administration of methotrexate and L-asparaginase is equally effective. The duration of second CR is short for all chemotherapeutic regimens.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 341-344 |
| Number of pages | 4 |
| Journal | American Journal of Hematology |
| Volume | 45 |
| Issue number | 4 |
| State | Published - 1994 |
Fingerprint
Keywords
- acute lymphoblastic leukemia
- reinduction regimens
- remission
- treatment
ASJC Scopus subject areas
- Hematology
Cite this
Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. / Welborn, Jeanna L.
In: American Journal of Hematology, Vol. 45, No. 4, 1994, p. 341-344.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults
AU - Welborn, Jeanna L
PY - 1994
Y1 - 1994
N2 - The clinical outlook for adults with acute lymphoblastic leukemia (ALL) has improved with the use of intensive chemotherapy. Complete remissions (CR) are achieved in 80% of adults but the majority relapse on maintenance chemotherapy and a few exhibit primary resistance to induction therapy. This report compares the various salvage treatments and provides guidance in selecting a regimen with the optimum clinical outcome. Regimens using high- dose ara-C (HDAC) in combination with mitoxantrone, amsacrine, or idarubicin are superior to HDAC alone or with L-asparaginase. The sequential administration of methotrexate and L-asparaginase is equally effective. The duration of second CR is short for all chemotherapeutic regimens.
AB - The clinical outlook for adults with acute lymphoblastic leukemia (ALL) has improved with the use of intensive chemotherapy. Complete remissions (CR) are achieved in 80% of adults but the majority relapse on maintenance chemotherapy and a few exhibit primary resistance to induction therapy. This report compares the various salvage treatments and provides guidance in selecting a regimen with the optimum clinical outcome. Regimens using high- dose ara-C (HDAC) in combination with mitoxantrone, amsacrine, or idarubicin are superior to HDAC alone or with L-asparaginase. The sequential administration of methotrexate and L-asparaginase is equally effective. The duration of second CR is short for all chemotherapeutic regimens.
KW - acute lymphoblastic leukemia
KW - reinduction regimens
KW - remission
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=0028298089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028298089&partnerID=8YFLogxK
M3 - Article
C2 - 7909983
AN - SCOPUS:0028298089
VL - 45
SP - 341
EP - 344
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 4
ER -